Detection methods predict differences in biology and survival in breast cancer patients

BMC Cancer

Maximino Redondo⁴  Rafael Funez⁵  Francisco Medina-Cano¹  Isabel Rodrigo⁵  Mercedes Acebal⁸  Teresa Tellez⁴  M Jose Roldan⁴  M Luisa Hortas⁴  Ana Bellinvia³  Teresa Pereda⁵  Laia Domingo⁷  María Morales-Suarez Varela²  Maria Sala⁷  Antonio Rueda⁶ 

[1] Department of Surgery, Hospital Costa del Sol, 29600, Marbella, Málaga, Spain

[2] Unit of Public Health and Environmental Care, Department of Preventive Medicine, CIBER ESP, University of Valencia, Valencia, Spain

[3] Department of Radiology, Hospital Costa del Sol, 29600, Marbella, Málaga, Spain

[4] Research Unit, Hospital Costa del Sol, University of Málaga, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Carretera de Cádiz Km 187, 29600, Marbella, Málaga, Spain

[5] Department of Pathology, Hospital Costa del Sol, 29600, Marbella, Málaga, Spain

[6] Department of Medical Oncology, Hospital Costa del Sol, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), 29600, Marbella, Málaga, Spain

[7] Epidemiology and Evaluation Department. IMIM Hospital del Mar, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC). Parc de Salut Mar, Universitat Autònoma de Barcelona, Catalonia, Spain

[8] Department of Radiology, Hospital Clinico Universitario Virgen de la Victoria, Campus Universitario Teatinos, 29010, Málaga, Spain

关键词: Survival;    Apoptosis;    Proliferation;    Detection methods;    Breast cancer;   

Others  :  1080010
DOI  :  10.1186/1471-2407-12-604

 received in 2012-06-13, accepted in 2012-12-13,  发布年份 2012

【 摘 要 】

Background

The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences.

Methods

For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors.

Results

After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more often than did symptomatic cancers (OR = 3.38, CI = 1.72-6.63 and OR = 3.44, CI = 1.94-6.10, respectively). Furthermore, the expression of bcl-2, a marker of good prognosis in breast cancer, was higher and HER2/neu expression was lower in screen-detected cancers than in symptomatic cancers (OR = 1.77, CI = 1.01-3.23 and OR = 0.64, CI = 0.40-0.98, respectively). However, when comparing prevalent vs incident screen-detected carcinomas, prevalent tumors were larger (OR = 2.84, CI = 1.05-7.69), were less likely to be HER2/neu positive (OR = 0.22, CI = 0.08-0.61) and presented lower Ki67 expression (OR = 0.36, CI = 0.17-0.77). In addition, incident tumors presented a shorter survival time than did prevalent ones (RR = 4.88, CI = 1.12-21.19).

Conclusions

Incident carcinomas include a variety of screen-detected carcinomas that exhibit differences in biology and prognosis relative to prevalent carcinomas. The detection method is important and should be taken into account when making therapy decisions.

【 授权许可】

   
2012 Redondo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Vainio H: IARC Handbooks of cancer prevention: breast cancer screening. IARC press, Lyon; 2002.
• [2]Moller H, Davies E: Over-diagnosis in breast cancer screening. BMJ 2006, 332:691-692.
• [3]Dillon MF, Hill AD, Quinn CM, O'Doherty A, Crown J, Fleming FJ, McDermott EW, O'Higgins N: Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer. J Med Screen 2004, 11:130-134.
• [4]Welch HG, Black WC: Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997, 127:1023-1028.
• [5]Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292:1064-1073.
• [6]Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R: Pathologic findings from the breast cancer surveillance consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 2006, 106:732-42.
• [7]Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203.
• [8]Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 2008, 98:1741-1744.
• [9]Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC: Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009, 101:1338-1344.
• [10]Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ, Elston CW, Ellis IO, Blamey RW, Robertson JF: Screening interval breast cancers: mammographic features and prognosis factors. Radiology 1996, 199:811-817.
• [11]Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ: Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 1995, 31A:1830-1835.
• [12]Redondo M, García J, Villar E, Rodrigo I, Perea-Milla E, Serrano A, Morell M: Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003, 34:1283-9.
• [13]Lacroix M, Toillon RA, Leclercq G: Stable portrait of breast tumours during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004, 11:497-522.
• [14]Bernards R, Weinberg RA: A progression puzzle. Nature 2002, 418:823.
• [15]McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987, 10:5-9.
• [16]American Society of Clinical Oncology: Clinical practice guidelines for the use of tumour markers in breast and colorectal cancers. J Clin Oncol 1996, 14:2843-2877.
• [17]Lipponen P, Aaltomaa S, Kosma VM, Syrjänen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994, 30A:2068-2073.
• [18]Villar E, Redondo M, Rodrigo I, García J, Avila E, Matilla A: bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol 2001, 22:137-145.
• [19]Bhargava V, Kell DL, van de Rijn M, Warnke RA: Bcl2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994, 145:535-540.
• [20]Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006, 12:2468-2475.
• [21]Callagy GM, Webber MJ, Pharoah PD, Caldas C: Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153.
• [22]Kallioniemi OP, Kärkkäinen A, Auvinen O, Mattila J, Koivula T, Hakama M: DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. Int J Cancer 1988, 42:697-702.
• [23]Uyterlinde AM, Baak JP, Schipper NW, Peterse HJ, Meijer JW, Vooys PG, Matze E: Prognostic value of morphometry and DNA flow-cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients. Int J Cancer 1991, 48:173-181.
• [24]Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR: Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 1999, 5:2682-2688.
• [25]Olivotto IA, Mates D, Kan L, Fung J, Samant R, Burhenne LJ: Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia. Breast Cancer Res Treat 1999, 54:73-81.
• [26]Magee B, Stewart AL, Swindell R: Outcome of radiotherapy after breast conserving surgery in screen detected breast cancers. Clin Oncol 1999, 11:40-45.
• [27]Wintzer HO, Zipfel I, Schulte-Mönting J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumours and its relationship to prognosis. Cancer 1991, 67:421-428.
• [28]Merkel DE, McGuire WL: Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumours. Cancer 1990, 65:1194-1205.
• [29]Redondo M, Rodrigo I, Pereda T, Funez R, Acebal M, Perea-Milla E, Jimenez E: Effects of emergency admission and delays on prognosis in patients with breast carcinoma. Supp Care Cancer 2009, 17:595-599.